Donato Bacca

2.2k total citations · 1 hit paper
32 papers, 1.7k citations indexed

About

Donato Bacca is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Donato Bacca has authored 32 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hepatology, 22 papers in Epidemiology and 6 papers in Rheumatology. Recurrent topics in Donato Bacca's work include Hepatitis C virus research (27 papers), Liver Disease Diagnosis and Treatment (18 papers) and Hepatitis B Virus Studies (18 papers). Donato Bacca is often cited by papers focused on Hepatitis C virus research (27 papers), Liver Disease Diagnosis and Treatment (18 papers) and Hepatitis B Virus Studies (18 papers). Donato Bacca collaborates with scholars based in Italy, Brazil and Sweden. Donato Bacca's co-authors include Alessandra Mangia, Vito Carretta, Nicola Minerva, Angelo Andriulli, Mauro Annese, Gaetano Scotto, Rosanna Santoro, Mario Romano, F. Vinelli and Giovanni Ricci and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and PLoS ONE.

In The Last Decade

Donato Bacca

31 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3

2005 608 citations Alessandra Mangia, Rosanna Santoro et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donato Bacca Italy	16	1.6k	1.5k	170	107	52	32	1.7k
Rune Wejstål Sweden	23	1.9k 1.2×	1.8k 1.2×	260 1.5×	113 1.1×	30 0.6×	67	2.1k
R. Soffredini Italy	19	1.2k 0.7×	1.1k 0.8×	127 0.7×	87 0.8×	41 0.8×	63	1.3k
Corinne Castelnau France	22	2.4k 1.5×	2.3k 1.6×	190 1.1×	146 1.4×	25 0.5×	43	2.6k
Nai‐Jen Hou Taiwan	16	943 0.6×	917 0.6×	115 0.7×	65 0.6×	32 0.6×	38	1.1k
Li‐Po Lee Taiwan	18	1.1k 0.7×	1.0k 0.7×	142 0.8×	49 0.5×	30 0.6×	29	1.2k
M Duffaut France	16	971 0.6×	827 0.6×	158 0.9×	108 1.0×	21 0.4×	49	1.2k
Vito Carretta Italy	10	1.2k 0.8×	1.1k 0.8×	135 0.8×	93 0.9×	46 0.9×	21	1.3k
V. Carreño Spain	19	880 0.5×	864 0.6×	79 0.5×	98 0.9×	18 0.3×	66	1.1k
Valeria Piazzolla Italy	16	861 0.5×	910 0.6×	101 0.6×	121 1.1×	28 0.5×	43	1.1k
Linda Murray United States	2	1.1k 0.7×	914 0.6×	325 1.9×	45 0.4×	22 0.4×	2	1.2k

Countries citing papers authored by Donato Bacca

Since Specialization

Citations

This map shows the geographic impact of Donato Bacca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donato Bacca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donato Bacca more than expected).

Fields of papers citing papers by Donato Bacca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donato Bacca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donato Bacca. The network helps show where Donato Bacca may publish in the future.

Co-authorship network of co-authors of Donato Bacca

This figure shows the co-authorship network connecting the top 25 collaborators of Donato Bacca. A scholar is included among the top collaborators of Donato Bacca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donato Bacca. Donato Bacca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mangia, Alessandra, Giovanni Cenderello, Domenico Potenza, et al.. (2018). Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis. PLoS ONE. 13(7). e0200568–e0200568. 3 indexed citations

Mangia, Alessandra, Valeria Piazzolla, Michele Mazzola, et al.. (2018). High SVR rates in patients with and without cirrhosis treated in real life with Sofosbuvir/Velpatasvir (SOF/VEL) combination for 12 weeks without Ribavirin (RBV). Journal of Hepatology. 68. S273–S274. 1 indexed citations

Mangia, Alessandra, Alexander Thompson, Rosanna Santoro, et al.. (2011). Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology. 54(3). 772–780. 50 indexed citations

Mangia, Alessandra, Giuseppe Montalto, Leonardo Mottola, et al.. (2010). Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. Journal of Hepatology. 53(6). 1000–1005. 18 indexed citations

Mangia, Alessandra, Alexander Thompson, Rosanna Santoro, et al.. (2010). An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response. Gastroenterology. 139(3). 821–827.e1. 250 indexed citations

Mangia, Alessandra, Nicola Minerva, Donato Bacca, et al.. (2008). Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection #. Hepatology. 49(2). 358–363. 46 indexed citations

Andriulli, Angelo, Carmela Cursaro, Raffaele Cozzolongo, et al.. (2008). Early discontinuation of ribavirin in HCV‐2 and HCV‐3 patients responding to Peg‐interferon alpha‐2a and ribavirin. Journal of Viral Hepatitis. 16(1). 28–35. 4 indexed citations

Mangia, Alessandra, Nicola Minerva, Donato Bacca, et al.. (2007). Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology. 47(1). 43–50. 181 indexed citations

Mangia, Alessandra, Rosanna Santoro, Nicola Minerva, et al.. (2005). Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3. New England Journal of Medicine. 352(25). 2609–2617. 608 indexed citations breakdown →

10.

Mangia, Alessandra, Giorgio Ricci, Marcello Persico, et al.. (2005). A randomized controlled trial of pegylated interferon α‐2a (40 KD) or interferon α‐2a plus ribavirin and amantadine vs interferon α‐2a and ribavirin in treatment‐naïve patients with chronic hepatitis C. Journal of Viral Hepatitis. 12(3). 292–299. 42 indexed citations

11.

Andriulli, Angelo, Marcello Persico, A. Iacobellis, et al.. (2004). Treatment of patients with HCV infection with or without liver biopsy. Journal of Viral Hepatitis. 11(6). 536–542. 15 indexed citations

12.

Mangia, Alessandra, Giorgio Ricci, Mario Romano, et al.. (2004). 93 HCV genotype 2 and 3 can be cured by PEG-IFN-alfa-2B and RBV for 12 wks: A randomized controlled study. Journal of Hepatology. 40. 34–34. 6 indexed citations

13.

Bárbaro, Giuseppe, Benvenuto Grisorio, Donato Bacca, et al.. (2003). Good Safety Profile and Efficacy of Leucocyte Interferon-?? in Combination with Oral Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C. BioDrugs. 17(6). 433–439.

14.

Mangia, Alessandra, Marcello Persico, Vito Carretta, et al.. (2003). A randomised controlled trial on pegylated interferon alfa-2a (40kd) (Pegasys) or IFN alfa-2a (ROFERON-A) plus ribavrin (RBV) and amantadine (AMA) vs IFN alfa-2a and RBV in naïve patients with chronic HCV. Journal of Hepatology. 38. 153–153. 1 indexed citations

15.

Mangia, Alessandra, Rosanna Santoro, Gioacchino Leandro, et al.. (2002). High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. Journal of Hepatology. 37(1). 109–116. 17 indexed citations

16.

Barbaro, Giuseppe, F Zechini, Adriano Pellicelli, et al.. (2001). Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. Journal of Hepatology. 35(3). 406–411. 107 indexed citations

17.

Mangia, Alessandra, Nicola Minerva, Mauro Annese, et al.. (2001). A Randomized Trial of Amantadine and Interferon Versus Interferon Alone As Initial Treatment for Chronic Hepatitis C. Hepatology. 33(4). 989–993. 45 indexed citations

18.

Bárbaro, Giuseppe, Gabriella Di Lorenzo, G Belloni, et al.. (1999). Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. The American Journal of Medicine. 107(2). 112–118. 59 indexed citations

19.

Bárbaro, Giuseppe, Gabriella Di Lorenzo, Maurizio Soldini, et al.. (1998). Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology. 28(2). 374–378. 75 indexed citations

20.

Bárbaro, Giuseppe, Gabriella Di Lorenzo, Maurizio Soldini, et al.. (1998). Interferon-α-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-α alone: an italian multicenter, randomized, controlled, clinical study. The American Journal of Gastroenterology. 93(12). 2445–2451. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact